spec sheet9 rows
Astra2959 is an obscure research chemical identified by vendors as N,N-dimethyl-3,3-diphenylcyclobutanamine hydrochloride, the N,N-dimethyl analog of 3,3-diphenylcyclobutanamine. The parent scaffold is a psychostimulant originally explored as an antidepressant in the late 1970s that inhibits reuptake of serotonin, norepinephrine and dopamine; the N,N-dimethyl form is reported to be the most potent locomotor stimulant of the series. Rigorous, compound-specific published data on Astra2959 itself are essentially absent.
- Presumed stimulant effect: Inferred from its monoamine-reuptake-inhibiting parent class, not directly demonstrated.
- Chemical-class interest: Represents a little-studied branch of the diphenylcyclobutanamine antidepressant/stimulant family.
Overview
Publicly available information on Astra2959 is very limited and comes largely from research-chemical vendors rather than the peer-reviewed literature. The name appears to reference an AstraZeneca-associated internal code for a member of the diphenylcyclobutanamine class, marketed for laboratory use only.
The underlying chemistry is better documented for the parent, 3,3-diphenylcyclobutanamine, a compound investigated in the 1970s as an antidepressant with psychostimulant properties. It and its N-methyl and N,N-dimethyl analogs are described as monoamine reuptake inhibitors, with the fully methylated (N,N-dimethyl) analog reported as the strongest locomotor stimulant among them in animal testing. On that basis, Astra2959 would be expected to behave as a triple monoamine reuptake inhibitor with stimulant character, but this is an inference from the compound class rather than a directly demonstrated finding.
Because no reliable clinical or even substantial preclinical literature specific to Astra2959 could be located, any account of its potency, safety or effects should be treated as provisional. It should be regarded as a poorly characterised research chemical, and claims about cognitive or mood benefits are not supported by dedicated evidence.
- Astra2959 belongs to the diphenylcyclobutanamine family first explored as antidepressants in the 1970s.
- Its N,N-dimethyl structure is the feature reported to make this branch of the series the strongest stimulant.
Mechanism
By analogy to the 3,3-diphenylcyclobutanamine class to which it belongs, Astra2959 is expected to inhibit the reuptake of , and , increasing monoamine levels and producing psychostimulant and potentially mood-elevating effects; the N,N-dimethyl substitution is associated with the greatest locomotor stimulation in the series. This mechanism is inferred from the parent scaffold rather than confirmed by studies on Astra2959 specifically, and the details of its transporter selectivity and potency in humans are unknown.
receptor fingerprint
Monoamine transporters (/NET/SERT)presumed reuptake inhibition (inferred from parent class)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
There is no meaningful safety data for Astra2959. As an obscure stimulant-class research chemical sold explicitly for laboratory use and not for human consumption, its toxicity, effective dose, drug interactions and long-term risks are unknown. Compounds that inhibit monoamine reuptake carry general risks including elevated heart rate and blood pressure, insomnia, anxiety and, in combination with other serotonergic or stimulant agents, serotonin toxicity or cardiovascular strain. It should not be ingested; treat it strictly as an uncharacterised experimental substance.
History
The diphenylcyclobutanamine scaffold behind Astra2959 dates to antidepressant and stimulant research in the 1970s. The specific 'Astra2959' designation points to work associated with AstraZeneca (or its predecessor Astra) on this compound class, but no substantial development history or publications specific to this code are available in the public record; it survives mainly as a niche research-chemical listing.
Reputation
Astra2959 is essentially unknown outside a handful of research-chemical vendors, with no established reputation, user base or expert commentary. In the nootropic community it is a fringe curiosity, and the honest position is that too little is known to characterise it reliably.
Subjective profileweighing the evidence above
Nothing is known about this. The stimulant effect is inferred from a parent scaffold, there is no toxicology, no dose and no human data, and it is sold for laboratory use for exactly that reason. Not worth anyone's money or risk.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Astra2959?
Vendors identify it as N,N-dimethyl-3,3-diphenylcyclobutanamine hydrochloride, an obscure member of a 1970s stimulant/antidepressant chemical class; almost nothing is published about this specific compound.
Is it safe to take?
No information supports safe human use. It is an uncharacterised research chemical sold for laboratory purposes and should not be ingested.
Limitations of the evidence
- Unknown risk profile: No toxicology or human data; stimulant-class cardiovascular and neurological risks are plausible.
Notes and cautions
- Not for consumption: Sold for laboratory use only with no safety characterisation.